Clinical Updates in Type 2 Diabetes
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
eBook Reader
 |
Guidelines
Standards of medical care in diabetes—2017.
The ADA’s Standards of Care provide clinicians, patients, researchers, payers, and other interested individuals with the components of good diabetes management, general treatment goals, and tools to evaluate the quality of care. Importantly, these recommendations should be adjusted based on individual preferences, comorbidities, and other patient-related factors.
American Diabetes Association. Diabetes Care. 2017;40(suppl 1):S1-S135.
AACE/ACE Comprehensive Diabetes Management Algorithm 2017.
The AACE/ACE algorithm provides recommendations on evaluating the whole patient, outlines potential risks and complications, and highlights evidence-based treatment approaches for diabetes. The document contains sections on lifestyle changes, considerations for obese individuals, prediabetes, glycemic goals, antihyperglycemic therapies, treatment algorithms, modifications for atherosclerotic cardiovascular disease risk factors, and overall principles of diabetes management.
Garber AJ, et al. Endocr Pract. 2017;23(2):207-238.
Patient and Caregiver Resources
Diabetes HealthSense
Created as part of the National Diabetes Education Program, Diabetes HealthSense includes easily accessible resources that can help patients live well and meet their goals—whether they have diabetes or are at risk for the disease.
Decision Aids for T2DM
To facilitate shared decision making, these examples of medication choice decision aids from the Mayo Clinic are organized into 7 issues that may be of interest to patients with T2DM. A video demonstrating the use of these cards can be found at: www.youtube.com/watch?v=SYTPqceFgSw.
Suggested Readings
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
Aroda VR, et al. Diabetes Care. 2016;39(11):1972-1980.
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell JE, Drucker DJ. Cell Metab. 2013;17:819-837.
From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.
Defronzo RA. Diabetes. 2009;58(4):773-795.
Minimizing hypoglycemia in diabetes.
International Hypoglycemia Study Group. Diabetes Care. 2015;38(8):1583-1591.
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Inzucchi SE, et al. Diabetes Care. 2015;38(1):140-149.
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I, et al. JAMA. 2016;315(9):898-907; requires registration for a free personal account.
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.
Linjawi S, et al. Diabetes Ther. 2017;8(1):101-114
Liraglutide and renal outcomes in type 2 diabetes.
Mann JFE, et al. N Engl J Med. 2017;377(9):839-848.
Liraglutide and cardiovascular outcomes in Type 2 diabetes.
Marso SP, et al. N Engl J Med. 2016;375(4): 311-322.
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso SP, et al. N Engl J Med. 2017;377(8):723-732.
Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.
Pfeffer MA, et al. N Engl J Med. 2015;373(23):2247-2257.
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
Rodbard HW, et al. Diabetes Obes Metab. 2016;18(1):40-48.
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Rosenstock J, et al. Diabetes Care. 2016;39(11):2026-2035.
Type 2 diabetes patients reach target glycemic control faster using IDegLira than either insulin degludec or liraglutide given alone.
Vilsbøll T, et al. Clin Drug Investig. 2016;36(4):293-303.
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Relevant Resources
Mechanism-Based Strategies to Achieve Patient-Centered Care
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Individualizing Evidence-Based Care
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
Looking Beyond Hemoglobin A1c
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Implications for PCSK9 Inhibitors in Clinical Practice
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Multidimensional Outcomes With SGLT2 Inhibitors
New Avenues to Improve Patient Outcomes
Best Practices for Screening, Diagnosis, and Management
